Skip to main content

Prise en charge d’une MICI avec une hépatopathie chronique

  • Chapter
Post’U FMC-HGE
  • 167 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Biancone L et al. Hepatitis B and C virus infection in Crohn’s disease. Inflamm Bowel Dis 2001;7:287–94.

    Article  PubMed  CAS  Google Scholar 

  2. Loras C et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009;104:57–63.

    Article  PubMed  CAS  Google Scholar 

  3. Vivarelli M et al. Influence of steroids on HCV recurrence after liver transplantation. A prospective study. J Hepatol 2007;47:793–8.

    Article  PubMed  CAS  Google Scholar 

  4. Nissen MJ et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology 2005;44:1016–20.

    Article  PubMed  CAS  Google Scholar 

  5. Aslanidis S, Vassiliadis T, Pyrpasopoulou A et al. Inhibition of TN Falpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007;26:261–4.

    Article  PubMed  CAS  Google Scholar 

  6. Campbell S, Ghosh S. Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001;13:191–2.

    Article  PubMed  CAS  Google Scholar 

  7. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004;51:580–4.

    Article  PubMed  Google Scholar 

  8. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004;51:800–4.

    Article  PubMed  CAS  Google Scholar 

  9. Vauloup C et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006;17:290–3.

    PubMed  CAS  Google Scholar 

  10. Peterson JR et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Rheum Dis 2003;62:1078–82

    Article  CAS  Google Scholar 

  11. Zein NM. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C infection: a phase 2 randomized, double blind, placebo-controlled study. J Hepatol 2005;42:315–22.

    Article  PubMed  CAS  Google Scholar 

  12. Villa F et al. Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. Eur J Gastroenterol Hepatol 2005;17:1243–5.

    Article  PubMed  Google Scholar 

  13. Salcedo-Mora X et al. Chronic hepatitis C and Crohn’s disease: nosoco-mial infection treatment with PEG-interferon plus ribavirin. Digestion 2006;73:210–4.

    Article  PubMed  CAS  Google Scholar 

  14. Tilg H et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003;52:1728–33.

    Article  PubMed  CAS  Google Scholar 

  15. Peyrin-Biroulet L etal. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment Pharmacol Ther 2008;28: 984–93.

    Article  PubMed  CAS  Google Scholar 

  16. Melmed GY et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101:1834–40.

    Article  PubMed  Google Scholar 

  17. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507–39.

    Article  PubMed  CAS  Google Scholar 

  18. Cheng AL et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV carriers with lymphoma. Hepatology 2003;37:1320–8.

    Article  PubMed  CAS  Google Scholar 

  19. Esteve M et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004;53:1363–5.

    Article  PubMed  CAS  Google Scholar 

  20. Millonig G et al. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol 2006;12: 974–6.

    PubMed  Google Scholar 

  21. Ojiro K et al. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J Gastroenterol 2008;43:397–401.

    Article  PubMed  Google Scholar 

  22. Madonia S et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508–9.

    Article  PubMed  Google Scholar 

  23. Yeo W et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299–307.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Michel Greff (Président FMC-HGE)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Bronowicki, J.P. (2009). Prise en charge d’une MICI avec une hépatopathie chronique. In: Greff, M. (eds) Post’U FMC-HGE. Springer, Paris. https://doi.org/10.1007/978-2-287-99247-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-99247-6_3

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-99246-9

  • Online ISBN: 978-2-287-99247-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics